Treatment of Advanced Lymphomas with Bleomycin (NSC-125066)

Publisher Website
Google Scholar
Abstract
Eighty-eight patients with advanced lymphomatous malignancy were treated with blecomycin given by i.m. or i.v. injection according to a randomized treatment assignment. Response occured most frequently in Hodgkin''s disease (i.m. 7/24; i.v. 4/18), least often in histiocytic lymphomas (i.m. 0/8; i.v. 1/8), and with intermediate frequency in lymphocytic lymphomas (i.m. 3/16; i.v. 0/14). While toxicity was common (70%), severe toxicity was unusual (8%) with severe pulmonary toxicity occurring in 4 patients (3 i.m.; 1 i.v.). All 3 drug associated deaths occurred in i.m. patients. Unexpected life threatening pericarditis occurred in 2 i.m. treated patients. Although response and drug related deaths occurred more often in the i.m. patients, comparison with i.v. patients was not statistically different.

This publication has 0 references indexed in Scilit: